RESUMO
BACKGROUND: Although the value of digitalis glycosides in the treatment of heart failure is limited, approximately 255 million DDDs of digitalis glycosides (DGs) were prescribed in Germany in 2004. METHOD: The authors analyzed data from adverse drug reactions (ADRs) resulting in hospitalization in the four German Pharmacovigilance Centers (PVCs) associated with DGs between 2000 and 2004. All patients with an at least "probable" ADR were included. RESULTS: Out of 3,092 ADR patients, in 314 patients (10.2%, 244 women) admission was caused by a DG-related ADR. Patients with DG-related ADR had a significantly lower body weight and were significantly older than patients with other ADRs. Per 1,000 patients exposed to DGs the incidence [95% CI] was calculated to 1.9 [1.0; 3.3] ADRs per 3 months exposition. Oral digitoxin was involved in 296 patients (228 women). 70.6% of women but only 29.3% of men were overdosed (> 1 mug/kg body weight per day). Women received significantly higher body weight-related digitoxin doses and had significantly higher digitoxin plasma levels than men. ADRs in patients with nonelevated digitoxin serum level were mainly caused by pharmacodynamic drug-drug interactions (e.g., beta-blockers). Overall, 42.4% of the ADRs were supposed to be preventable. CONCLUSION: Body weight-adapted dosing of digitoxin is essential for preventing DG-ADRs, particularly in elderly women with low body weight. Beyond giving attention to pharmacodynamic and pharmakokinetic drug-drug interactions, regular measurements of digitoxin plasma concentrations are crucial accounting for the increased half-life of digitoxin in the very old.
Assuntos
Arritmias Cardíacas/tratamento farmacológico , Cardiotônicos/toxicidade , Glicosídeos Digitálicos/toxicidade , Insuficiência Cardíaca/tratamento farmacológico , Admissão do Paciente/estatística & dados numéricos , Sistemas de Notificação de Reações Adversas a Medicamentos , Idoso , Idoso de 80 Anos ou mais , Arritmias Cardíacas/sangue , Arritmias Cardíacas/epidemiologia , Cardiotônicos/administração & dosagem , Cardiotônicos/farmacocinética , Glicosídeos Digitálicos/administração & dosagem , Glicosídeos Digitálicos/farmacocinética , Relação Dose-Resposta a Droga , Interações Medicamentosas , Monitoramento de Medicamentos , Feminino , Alemanha , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/epidemiologia , Humanos , Incidência , Masculino , Pessoa de Meia-IdadeRESUMO
The lessons that the physician William Withering learned from his studies of digitalis are still relevant today. This paper highlights four of these lessons and updates them using the tools of clinical pharmacology and pharmacoepidemiology. First, Withering learned that failure to prepare digitalis from the foxglove in a standard manner resulted in a product with unpredictable clinical effects. Preparation of medicines from plants since then has not followed similar good practice and medicines have often not been granted marketing authorisation because of variability in their quality. Second, differences in the response to digitalis were noted by Withering, but he had little idea of their basis. Clinical pharmacology has shown that for drugs such as digitalis differences are caused by variability both in receptor sensitivity and in drug disposition. Third, the dose-response characteristics of digitalis were well known to Withering. Modern techniques of measuring response, such as the use of biomarkers, have made such studies easier, although clinical observations remain the gold standard. Fourth, Withering documented many of the adverse effects of digitalis. The use of various modern databases has facilitated the analysis of clinical toxicology and thus of risk-benefit profiles.
Assuntos
Glicosídeos Digitálicos/farmacocinética , Fitoterapia , Disponibilidade Biológica , Digitalis , Glicosídeos Digitálicos/efeitos adversos , Glicosídeos Digitálicos/história , Relação Dose-Resposta a Droga , Inglaterra , História do Século XVIII , Farmacologia Clínica , Fitoterapia/história , Folhas de Planta , Preparações de Plantas/efeitos adversos , Preparações de Plantas/história , Preparações de Plantas/farmacocinéticaRESUMO
The intestinal absorption of digoxin is essentially a passive non-saturable diffusion process, although a saturable carrier-mediated component also plays an important role. The bioavailability varies between 40 and 100%: the presence of food may reduce the peak serum concentration, but does not reduce the amount of digoxin absorbed. Recent development of a capsule containing a hydroalcoholic vehicle may reduce interindividual variations in absorption. Pharmacokinetic analysis of the distribution of digoxin suggests 3 compartments, the slow distribution phase accounting for the lag time between the inotropic effects and the plasma concentration profile. Digoxin is extensively bound to tissues such as myocardium, renal, skeletal muscle as well as red blood cells, but not to adipose tissue. Plasma protein binding varies between 20 and 30%: displacement of digoxin from protein binding sites does not cause significant clinical effects. As expected, haemodialysis or exchange transfusions do not significantly alter the body load of digoxin. The apparent volume of distribution of digoxin varies between 5 and 7.3 L/kg; this may be reduced by, for example, electrolyte abnormalities which reduce digoxin binding to the myocardium. The elimination half-life of digoxin is 36 hours, with 60 to 80% being excreted unchanged, by passive glomerular filtration and active tubular secretion. The remainder is excreted non-renally. Clearance is therefore dependent on renal function and declines in renal disease and in elderly patients. Digoxin interacts with other drugs at any stage of absorption (e.g. cholestyramine), distribution (e.g. quinidine), metabolism (e.g. phenytoin) or elimination (e.g. diltiazem). Patients should, therefore, be carefully monitored when changing a therapeutic regimen which includes any drugs known to interact with digoxin. Clinical monitoring is more important than therapeutic drug monitoring which should be reserved for suspected toxicity, doubts about efficacy, or in cases of poor compliance. With the advent of newer treatment modalities, digoxin is no longer the treatment of first choice in supraventricular arrhythmias and congestive heart failure. However, with careful monitoring, digoxin remains an important therapeutic option.
Assuntos
Glicosídeos Digitálicos/farmacocinética , Glicosídeos Digitálicos/uso terapêutico , Humanos , Monitorização FisiológicaRESUMO
Cardiopulmonary bypass is accompanied by profound changes in the organism that may alter the pharmacokinetics of drugs. Drug distribution can be altered, for example, by changes in blood flow and by haemodilution, with a decrease in protein binding; a decrease in the elimination of some drugs can be caused by impairment of renal or hepatic clearance, due, for example, to lowered perfusion and hypothermia. The subject was reviewed in the Journal in 1982, and the emphasis of the present review is on new data related to specific drugs. The following substances are dealt with: benzodiazepines, cephalosporins, digitalis glycosides, general anaesthetics, glyceryl trinitrate (nitroglycerin), lignocaine (lidocaine), muscle relaxants, nitroprusside, opiates, papaverine and propranolol. For many of these substances an abrupt decrease has been observed in serum concentration upon initiation of bypass, which is explained by haemodilution and an increase in distribution due to decreased protein binding. For nitrates and some opiates, adsorption to the bypass apparatus was shown to be important. The gradual increase in serum concentrations seen during cardiopulmonary bypass with some drugs after the initial fall is usually explained by redistribution of the drug and/or decrease in its elimination. The same phenomena are thought to explain why in the post-bypass period a concentration increase occurs, or at least a slower decrease than expected. However, drug elimination has been directly measured in only a few studies. The short duration of the bypass procedure and the continuous changes during the process hamper a rigorous pharmacokinetic evaluation. Studies allowing more precise understanding of the mechanisms underlying the observed concentration changes are needed, but are difficult to design. Similarly, more data are awaited on the pharmacodynamic and clinical consequences of the concentration changes.
Assuntos
Ponte Cardiopulmonar , Farmacocinética , Anestésicos/farmacocinética , Benzodiazepinas/farmacocinética , Cefalosporinas/farmacocinética , Glicosídeos Digitálicos/farmacocinética , Humanos , Lidocaína/farmacocinética , Entorpecentes/farmacocinética , Fármacos Neuromusculares não Despolarizantes/farmacocinética , Nitroglicerina/farmacocinética , Nitroprussiato/farmacocinética , Papaverina/farmacocinética , Propranolol/farmacocinéticaRESUMO
Despite continuous controversy associated with a variety of aspects of the pharmacology of the cardiac glycosides, it appears that these agents will continue to be widely used in the future. Current methods for the measurement of digoxin are unreliable and allow measurement of both cardioinactive metabolites of digoxin and endogenous digoxin-like substances. As a result, the therapeutic monitoring of digoxin concentrations should, for the most part, be limited to an assessment of patient compliance and confirmation of a clinical impression of drug toxicity.
Assuntos
Glicosídeos Digitálicos/farmacocinética , Digoxina , Saponinas , Animais , Proteínas Sanguíneas/metabolismo , Cardenolídeos , Glicosídeos Digitálicos/farmacologia , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Imunoensaio/métodos , Monitorização Fisiológica/métodosRESUMO
Most pharmacokinetic and biologic attributes of digitalis are age dependent. They are determined in great measure by the chemical structure of the specific cardiac glycoside being used. These effects differ in the intact normal circulation and in heart failure because of the altered autonomic nervous system and hormonal control that exist in the latter. Digitalis is effective only in the presence of myocardial dysfunction, but in a clinical setting, cardiac performance may be difficult to gauge; improved tools are needed for this purpose. The dosages of digoxin recommended for infants and children have been steadily reduced in the past decade, and there is no good evidence that more favorable risk-to-benefit ratios are achieved when higher doses are used or when higher plasma concentrations are sought. Massive digitalis toxicity is a serious, often fatal, complication in young infants, especially when the drug is given parenterally; it may be difficult to diagnose early. The only reliable deterrent for this complication is the adoption of careful safety standards whenever the drug is employed. Experience with digoxin antibodies is still scarce in children, especially in infancy, but their use generally has been associated with a favorable outcome. Endogenous substances that interfere with the digoxin radioimmunoassay (DLIS) occasionally yield clinically relevant, erroneously high, plasma digoxin concentration readings in neonates. An interesting hypothesis currently being investigated is the physiologic and pathologic role of these compounds in sodium hemostasis; they may be part of a putative endogenous NaK-ATP-ase inhibitor involved in the pathogenesis of hypertension and renal diseases.
Assuntos
Glicosídeos Digitálicos/farmacologia , Digoxina/imunologia , Homeostase/efeitos dos fármacos , Fragmentos Fab das Imunoglobulinas , Reações Cruzadas , Glicosídeos Digitálicos/efeitos adversos , Glicosídeos Digitálicos/farmacocinética , Digoxina/farmacocinética , Digoxina/uso terapêutico , Feminino , Humanos , Fragmentos Fab das Imunoglobulinas/uso terapêutico , Recém-Nascido , Gravidez , Sódio/fisiologiaRESUMO
Heart failure may have repercussions on the different stages of pharmacokinetics. Following intramuscular or oral administration, drug absorption may be slowed down by the fall in cardiac output and by peripheral vasoconstriction. Tissue distribution is altered by changes in the plasma protein binding of drugs and by redistribution of cardiac output to the brain and heart, resulting in changes in the apparent volume of distribution. Excretion through the liver is influenced by the decrease of hepatic blood flow and metabolic capacities. Lowering of the renal blood flow alters the glomerular and tubular excretion processes. These hepatic and renal dysfunctions result in a reduction of total plasma clearance. The effects of heart failure on the pharmacokinetics of digitalis compounds seem to consist merely of a delay in digestive tract absorption. More studies have been devoted to the fate of antiarrhythmic agents. Blood concentrations of lidocaine are raised in patients with heart failure; this is accounted for by the redistribution of local blood flows, the increase in plasma protein binding observed after myocardial infarction and the reduced hepatic clearance. A fall in the volume of distribution and total clearance of quinidine has been described. Data concerning disopyramide are discordant, but reduction of the free drug fraction and variations in total clearance have been observed after myocardial infarction. Alterations in the total clearance of prazosin, nitroglycerin and theophylline have been reported by several authors.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Insuficiência Cardíaca/fisiopatologia , Farmacocinética , Antiarrítmicos/farmacocinética , Débito Cardíaco , Glicosídeos Digitálicos/farmacocinética , Humanos , Absorção Intestinal , Distribuição Tecidual , VasoconstriçãoRESUMO
The intestinal epithelial cell layer is the first major barrier to absorption encountered by xenobiotics. An understanding of the mechanism and sites of drug absorption and metabolism is thus a critical first step in developing orally active compounds. In this context human brush-border membrane vesicles obtained from multi-organ donor intestines have been purified. This model has been validated and used to investigate the duodenal absorption of drugs "in vitro", namely digitalis. It is well established that digitalis compounds present great variability in their respective "in vivo" bioavailability in human (60-90% for digoxin, 0% for ouabain). These particular characteristics prompted us to determine whether this membrane model constitutes a suitable tool in predicting the bioavailability or intestinal transport processes of these molecules. The uptake of [3H] digoxin and [3H] ouabain by membrane vesicles incubated in media of increasing osmolarities demonstrated that: i/two factors are involved in the uptake processes of digoxin: membrane binding and intravesicular transport (osmotic sensitive), ii/ for ouabain, no osmotic sensitivity was observed, indicating that no transport process occurred, but only membrane binding processes. These results are in complete agreement with the absolute bioavailability data reported for man "in vivo". This human brush-border model constitutes an interesting approach to the intestinal absorption phenomena which are known to be among the factors influencing the bioavailability of orally administered drugs.
Assuntos
Glicosídeos Digitálicos/farmacocinética , Duodeno/metabolismo , Absorção Intestinal/fisiologia , Disponibilidade Biológica , Transporte Biológico Ativo/fisiologia , Biomarcadores , Membrana Celular/metabolismo , Digoxina/farmacocinética , Duodeno/enzimologia , Humanos , Técnicas In Vitro , Membranas/metabolismo , Microscopia Eletrônica , Microvilosidades/enzimologia , Microvilosidades/metabolismo , Ouabaína/farmacocinética , Ácido Taurocólico/metabolismo , TemperaturaRESUMO
The experimental and clinical evidence on the decreased efficacy of digitalis on old age are reviewed. The trials on the efficacy of digitalis on elderly in heart failure and sinus rythm, are analysed and we try to characterize the sub-group of responders. So we try to explain the criteria to choose the therapeutic dose, to avoid intoxication and to interpret the seric concentrations. We describe the pharmacocynetics of digitalis on old people on heart failure which can explain the susceptibility to intoxication. We reviewed the incidence of digitalis intoxication on old age and the difficulties on its recognition.
Assuntos
Arritmias Cardíacas/tratamento farmacológico , Baixo Débito Cardíaco/tratamento farmacológico , Glicosídeos Digitálicos/uso terapêutico , Digitalis , Plantas Medicinais , Plantas Tóxicas , Idoso , Glicosídeos Digitálicos/sangue , Glicosídeos Digitálicos/farmacocinética , HumanosRESUMO
Three cases of patients with symptoms of digitalis overdosage were presented. The principal manifestations included complex supraventricular dysrhythmias and atrio-ventricular conduction disturbances. In the discussion a special attention was paid to digitalis dosage. Multiple factors influencing plasma concentration of digitalis including pharmacokinetics, bioavailability and drug interactions with glycosides were described. Short review of toxic manifestations of digitalis was made and the treatment of digitalis intoxication was outlined.
Assuntos
Arritmias Cardíacas/induzido quimicamente , Nó Atrioventricular/efeitos dos fármacos , Glicosídeos Digitálicos/intoxicação , Digitalis/intoxicação , Plantas Medicinais , Plantas Tóxicas , Idoso , Idoso de 80 Anos ou mais , Captopril/farmacologia , Glicosídeos Digitálicos/administração & dosagem , Glicosídeos Digitálicos/farmacocinética , Interações Medicamentosas , Overdose de Drogas , Quimioterapia Combinada , Feminino , Sistema de Condução Cardíaco/efeitos dos fármacos , Humanos , Masculino , Medigoxina/farmacologia , Pessoa de Meia-Idade , Pentoxifilina/farmacologia , Taquicardia Supraventricular/induzido quimicamenteAssuntos
Antiarrítmicos/efeitos adversos , Glicosídeos Digitálicos/efeitos adversos , Antiarrítmicos/farmacocinética , Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/complicações , Arritmias Cardíacas/tratamento farmacológico , Glicosídeos Digitálicos/farmacocinética , Glicosídeos Digitálicos/uso terapêutico , HumanosAssuntos
Cardiotônicos/uso terapêutico , Glicosídeos Digitálicos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Animais , Cardiotônicos/farmacocinética , Cardiotônicos/farmacologia , Glicosídeos Digitálicos/farmacocinética , Glicosídeos Digitálicos/farmacologia , Feminino , Insuficiência Cardíaca/fisiopatologia , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , Infarto do Miocárdio/tratamento farmacológico , GravidezAssuntos
Bloqueadores dos Canais de Cálcio/farmacologia , Fígado/metabolismo , Antagonistas Adrenérgicos beta/farmacocinética , Carbamazepina/farmacocinética , Ciclosporinas/farmacocinética , Glicosídeos Digitálicos/farmacocinética , Interações Medicamentosas , Humanos , Prazosina/farmacocinética , Quinidina/farmacocinética , Teofilina/farmacocinéticaAssuntos
Amrinona/farmacologia , Glicosídeos Digitálicos/farmacologia , Insuficiência Cardíaca/tratamento farmacológico , Amrinona/farmacocinética , Amrinona/uso terapêutico , Animais , Glicosídeos Digitálicos/farmacocinética , Glicosídeos Digitálicos/uso terapêutico , Cobaias , Hemodinâmica/efeitos dos fármacos , Humanos , CoelhosAssuntos
Glicosídeos Digitálicos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Preparações de Ação Retardada , Glicosídeos Digitálicos/efeitos adversos , Glicosídeos Digitálicos/farmacocinética , Interações Medicamentosas , Tolerância a Medicamentos , Insuficiência Cardíaca/metabolismo , Humanos , Magnésio/metabolismo , Sódio/metabolismoRESUMO
In patients with heart failure and atrial fibrillation cardiac glycosides, generally in combination with beta-blockers, are indicated to control ventricular rate. In systolic heart failure and sinus rhythm, however, the use of digitalis continues to be debated. There are special concerns that cardiac glycosides might lead to an increased mortality rate in women. Retrospective analyses, however, do not indicate any sex-based differences in the effectiveness of cardiac glycosides. Beneficial effects of cardiac glycosides in heart failure seem to be related to the attenuation of sympathetic activation and neurohumoral alterations, which is already obtained at low digoxin serum concentrations, while high serum levels are associated with increased mortality. Therefore, in patients with sinus rhythm who remain symptomatic under an optimized therapy with ACE inhibitors, beta-blockers and diuretics in addition to digitalis should be considered regardless of the gender. However, target serum digoxin concentrations should be low in a range of 0.5 to 0.8 ng/ml.
Assuntos
Fibrilação Atrial/tratamento farmacológico , Glicosídeos Digitálicos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Antagonistas Adrenérgicos beta/efeitos adversos , Antagonistas Adrenérgicos beta/farmacocinética , Antagonistas Adrenérgicos beta/uso terapêutico , Fibrilação Atrial/sangue , Fibrilação Atrial/mortalidade , Glicosídeos Digitálicos/efeitos adversos , Glicosídeos Digitálicos/farmacocinética , Digoxina/efeitos adversos , Digoxina/farmacocinética , Digoxina/uso terapêutico , Relação Dose-Resposta a Droga , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/mortalidade , Humanos , Fatores de Risco , Fatores Sexuais , Análise de Sobrevida , Sistema Nervoso Simpático/efeitos dos fármacos , Resultado do TratamentoRESUMO
Many studies and cases of digitalis intoxication have been reported since the time of William Withering's first publication in 1785. Recognition and management of digitalis toxicity is challenging. Before digoxin immune Fab was commercially available, treatment consisted of managing the signs and symptoms of toxicity until the digitalis was eliminated. Digoxin immune Fab offers a safe, effective, and specific method of quickly reversing digitalis toxicity. Factors that must be considered with the clinical use of this agent include the dosage calculation, administration technique, postdose monitoring, pharmacokinetics, mechanism of action, interference with commercially available digoxin assays, partial neutralizing dosing, rebound of free digoxin, and indications for use. For severe, life-threatening toxicity, digoxin immune Fab is the treatment of choice.